People with obesity perhaps familiar with this drug as administered agent, Sibutramine, due to treats their diabetes.
Recently some country had observed about safety of this drug.
In the UK, this drug suspended related the safety concern.

In the US market, this drug branded as Meridia, Reductil and Sibutex that manufactured by Abbott Laboratories.

Recently FDA warned the manufacturer that should be labels for ‘not to use’ with patient that have cardiovascular history including with the patients that have history of;

- coronary artery disease
- stroke or transient ischemic attack
- heart arrhythmias
- congestive heart failure
- peripheral arterial disease, and
- uncontrolled high blood pressure (more than 145/90 mm Hg)

This warning based on data of 10,000 obese patients with have vary of above precaution disease history from the data at the Sibutramine Cardiovascular Outcomes Trial (SCOUT).

FDA noted to healthcare professional to monitor patients blood pressure due taking sibutramine.

EMEA, the Europe Medicines Agency issued press released related to the result data that “the risk of these medicines are greater than their benefits.”

Now in the UK and Europe country suspend the marketing authorization for these medicines.
Brand marketing of Sibutramine in UK and Europe are Reduxade, Reductil, and Zelium.

Moreover EMEA stated to the physicians should no longer prescribe Sibutramine administered agent, pharmaceutical should no longer dispense them, and the patients who had consume this medicine should seeing their physicians again.